Olive oil;Soybean oil

GOTHENBURG, Sweden, June 27, 2024 /PRNewswire/ -- Zinzino has today acquired 49% of the shares and votes in the Cypriot olive oil producer Cleanthi Alpha-Olenic LTD ("Cleanthi or the Company"). The acquisition is another strategically important step in Zinzino's growth plans focused on improving personal health and well-being on a global scale with innovative biotechnology and a pioneering product portfolio marketed through direct sales. Cleanthi is an olive oil producer with a unique and patented process of pressing olive oil originating from certified Koreneiki olives from orchards owned by farmers for several generations without the use of artificial fertilizers or pesticides. The manufacturing process enables the production of olive oil with up to 30 times the polyphenol content of regular olive oil. The business is currently run on a small scale, with most of the production going to Zinzino's existing products R.E.V.O.O. and BalanceOil Premium. Through the partnership, Zinzino gains access to Cleanthi's IP rights, which opens up opportunities to develop and increase brand protection for Zinzino's BalanceOil, the product group that currently accounts for about 60% of the Group's total revenue. Going forward, Zinzino intends to expand production at Cleanthi to secure olive oil supply for the increased internal demand arising from Zinzino's global expansion and high sales growth. At the same time, external revenues for Cleanthi can be increased similar to the model previously used successfully for the group's manufacturing unit, Faun Pharma AS in Norway. Zinzino initially acquires 49% of the shares in the Company and pays a fixed purchase price of EUR 1.9 million at closing, of which EUR 1.2 million in newly issued Zinzino shares. In addition, Cleanthi will receive EUR 0.5 million through a new issue of Zinzino. In addition, Zinzino also receives an option to acquire an additional 1% of the Company from the sellers for EUR 1. The cash part of the purchase price and the new share issue is financed through the group's own cash. A visionary mindset, tech-first perspective, test-based diet with cellular level nutrition and a strong position to capitalize on current trends will form the basis of the new partnership. Following the acquisitions of VMA Life in 2020, Enhanzz in 2022, the strategic partnership with ACN and the recently completed asset acquisition of Xelliss, Zinzino has been looking for additional powerful investments to maintain its sustainable, profitable growth, increase brand protection, strengthen its distribution power, expand into new markets and leverage the product portfolio in new consumer areas. - Individual advice and customized solutions are the future, and not just in health and wellness, says Dag Bergheim Pettersen, CEO of Zinzino. By working with Cleanthi, we are strengthening and advancing our brand protection and securing important olive oil production. Link to PM: For more information please contact: Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, e-mail: [email protected] Fredrik Nielsen CFO Zinzino +46 707 900 174, e-mail: [email protected] Images for free publication: [email protected] Certified advisor: Carnegie Investment Bank AB (publ.) This information is such that Zinzino AB (publ.) is obliged to make public according to the EU's market abuse regulation. The information was provided by the above contact person for publication at 11.00 on 27 June 2024. This information was brought to you by Cision . The following files are available for download:

In a new study that followed more than 25,000 initially healthy U.S. women for up to 25 years, researchers found that participants who had greater Mediterranean diet intake had up to 23% lower risk of all-cause mortality, with benefits for both cancer mortality and cardiovascular mortality. Investigators from Brigham and Women's Hospital identified and assessed underlying mechanisms that may explain the Mediterranean diet's 23 percent reduction in all-cause mortality risk for American women The health benefits of the Mediterranean diet have been reported in multiple studies, but there is limited long-term data of its effects in U.S. women and little understanding about why the diet may reduce risk of death. In a new study that followed more than 25,000 initially healthy U.S. women for up to 25 years, researchers from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, found that participants who had greater Mediterranean diet intake had up to 23% lower risk of all-cause mortality, with benefits for both cancer mortality and cardiovascular mortality. The researchers found evidence of biological changes that may help explain why: they detected changes in biomarkers of metabolism, inflammation, insulin resistance and more. Results are published in JAMA. "For women who want to live longer, our study says watch your diet! The good news is that following a Mediterranean dietary pattern could result in about one quarter reduction in risk of death over more than 25 years with benefit for both cancer and cardiovascular mortality, the top causes of death in women (and men) in the US and globally," said senior author Samia Mora, MD, a cardiologist and the director of the Center for Lipid Metabolomics at the Brigham. The Mediterranean diet is a plant-based diverse diet that is rich in plants (nuts, seeds, fruits, vegetables, whole grains, legumes). The main fat is olive oil (usually extra virgin), and the diet additionally includes moderate intake of fish, poultry, dairy, eggs, and alcohol, and rare consumption of meats, sweets, and processed foods. The current study investigated the long-term benefit of adherence to a Mediterranean diet in a U.S. population recruited as part of the Women's Health Study, and explored the biological mechanisms that may explain the diet's health benefits. The study investigators evaluated a panel of approximately 40 biomarkers representing various biological pathways and clinical risk factors. Biomarkers of metabolism and inflammation made the largest contribution, followed by triglyceride-rich lipoproteins, adiposity, insulin resistance. Other biological pathways relate to branched-chain amino acids, high-density lipoproteins, low-density lipoproteins, glycemic measures, and hypertension have smaller contribution. "Our research provides significant public health insight: even modest changes in established risk factors for metabolic diseases -- particularly those linked to small molecule metabolites, inflammation, triglyceride-rich lipoproteins, obesity, and insulin resistance -- can yield substantial long-term benefits from following a Mediterranean diet. This finding underscores the potential of encouraging healthier dietary habits to reduce the overall risk of mortality," said lead author Shafqat Ahmad, PhD, an associate professor of Epidemiology at Uppsala University Sweden and a researcher in the Center for Lipid Metabolomics and the Division of Preventive Medicine at the Brigham. The current study identifies important biological pathways that may help explain all-cause mortality risk. However, the authors note some key limitations, including that the study was limited to middle aged and older well-educated female health professionals who were predominantly non-Hispanic and white. The study relied on food-frequency questionnaires and other self-reported measures, such as height, weight and blood pressure. But the study's strengths include its large scale and long follow up period. The authors also note that as the concept of the Mediterranean diet has gained popularity, the diet has been adapted in different countries and cultures. "The health benefits of the Mediterranean diet are recognized by medical professionals, and our study offers insights into why the diet may be so beneficial. Public health policies should promote the healthful dietary attributes of the Mediterranean diet and should discourage unhealthy adaptations," said Mora.